

Table of Contents

CHAPTER 1

Cholesterol Biosynthesis in vitro. MARY E. DEMPSEY. With 27 Figures

I. Cell-Free Homogenates	1
II. Microsomal and Soluble Enzymes; Squalene and Sterol Carrier Protein Applications	5
A. Enzymes in the Early Stages of Cholesterol Synthesis	5
B. Enzymes in the Later Stages of Cholesterol Synthesis	5
C. Characteristics of Δ^5 -Dehydrogenase and Δ^7 -Reductase; Role of Squalene and Sterol Carrier Protein (SCP)	6
D. Inhibition of the Later Stages of Cholesterol Synthesis	10
III. Preparations and Activity Assays	12
A. HMG-CoA Reductase	14
B. Δ^5 -Dehydrogenase and Δ^7 -Reductase	14
C. Squalene and Sterol Carrier Protein (SCP)	15
D. Method 1	18
E. Method 2	19
F. Assay of HMG-CoA Reductase	22
G. Assay of Δ^5 -Dehydrogenase	22
H. Assay of Δ^7 -Reductase	23
I. Linearity of Enzymic Assays; Optimum Substrate Levels	25
J. Binding of Compounds to SCP and Microsomal Enzymes.	25
References	26

CHAPTER 2

Cholesterol Metabolism in Man. H. S. SODHI. With 12 Figures

I. Introduction	29
II. Distribution of Cholesterol in the Body	30
III. Functions of Cholesterol	31
IV. Synthesis of Cholesterol	33
A. Synthesis of Cholesterol in Various Tissues of the Body	34
B. Control of Endogenous Synthesis of Cholesterol	38
C. Diurnal Variation	41
D. Methods to Study Synthesis of Cholesterol in Man	43

V. Absorption of Dietary Cholesterol	45
A. Control Mechanisms Regulating Absorption of Cholesterol from the Intestinal Lumen	53
B. Methods to Study Absorption of Dietary Cholesterol	54
VI. Catabolism of Cholesterol and Its Losses from the Body Pools	55
A. Factors Influencing Catabolism of Endogenous Cholesterol	59
B. Skin	60
C. Adrenal Glands	60
VII. Plasma Cholesterol	61
VIII. Relationship of Cholesterol in Plasma and Tissue Pools	65
IX. Homeostasis of Plasma Cholesterol	69
Turnover of Cholesterol in Exchangeable Pools	72
X. Plasma Cholesterol Esters	75
XI. Proposed Model for Cholesterol Metabolism in Man	80
XII. Cholesterol Metabolism in Hyperlipoproteinemias	83
References	90

CHAPTER 3

Bile Acid Metabolism. T. A. MIETTINEN. With 3 Figures

I. Introduction	109
II. Enterohepatic Circulation	110
III. Different Parameters of Bile Acid Metabolism	113
A. Pool Size	114
B. Biliary Secretion	115
C. Intestinal Concentration	115
D. Reabsorption	116
E. Number of Enterohepatic Circulations	117
F. Faecal Excretion	117
G. Serum Bile Acids	118
H. Urinary Bile Acids	119
Daily Synthesis	121
IV. Regulation of Cholesterol Catabolism via Bile Acids	122
V. Physiological Factors Influencing Bile Acid Metabolism	126
Diet	126
VI. Effects of Hormones on Bile Acids	129
A. Pituitary Hormones	129
B. Sex Hormones	130
C. Thyroid Hormones	131
VII. Hyperlipidaemia	133
A. Chylomicronaemia (Type I)	133
B. Hypercholesterolaemia (Type II)	133
C. Familial Hyperlipoproteinaemia (Type III)	138

D. Hypertriglyceridaemia (Type IV)	138
E. Hyperglyceridaemia (Type V)	140
References	140

CHAPTER 4

Mechanisms of Hyperlipidemia. J. M. FELTS and L. L. RUDEL. With 3 Figures

I. Introduction	151
II. Normal Levels of Plasma Triglycerides and Cholesterol	151
III. The Plasma Lipoprotein Spectrum	152
A. Techniques of Analysis	154
1. Separation on the Basis of Density	154
a) The Analytical Ultracentrifuge	154
b) The Preparative Ultracentrifuge	154
2. Separation on the Basis of Charge by Zonal Electrophoresis	155
3. Gel Filtration Chromatography	155
4. Precipitation with Polyanion-Metal Complexes	156
B. Structure and Chemical Composition of Plasma Lipoproteins	158
C. Free Fatty Acids (FFA)	159
IV. The Metabolism of Constituents of Plasma Lipoproteins	159
A. Triglyceride Transport in Chylomicrons and VLDL	160
1. Intestinal Mucosal Cell	160
2. Liver	160
B. Cholesterol Transport in Chylomicrons and VLDL	161
1. Intestinal Mucosal Cell	161
2. Liver	162
C. Triglyceride Assimilation Mechanisms	162
1. Role of Liver	162
2. Role of Lipoprotein Lipase	163
D. Cholesterol Assimilation Mechanisms	166
V. Classification of Hyperlipidemias	168
A. Primary Hyperlipoproteinemias	170
1. Familial Type I Hyperlipoproteinemia (Familial Hyperchylomicronemia, Fat Induced Hyperlipidemia, Idiopathic Hyperlipemia)	170
2. Familial Type II Hyperlipoproteinemia (Familial Hypercholesterolemia; Familial Hypercholesterolemic Xanthomatosis	171
3. Familial Type III Hyperlipoproteinemia (Broad-Beta Disease, Remnant Disease)	174
4. Familial Type IV Hyperlipoproteinemia (Hyperprebetalipoproteinemia, Familial Hyperlipemia, Carbohydrate-Induced Hyperlipemia, Endogenous Hyperglyceridemia)	176
5. Familial Type V Hyperlipoproteinemia [Familial Mixed (Endogenous and Exogenous) Hyperlipemia, Familial Hyperprebetalipoproteinemia with Hyperchylomicronemia]	177

B. Secondary Hyperlipoproteinemias 178

1. Alcoholic Hyperlipoproteinemia 178

2. Diabetic Hyperlipoproteinemia 179

3. Hyperlipoproteinemia of the Nephrotic Syndrome. 180

4. Hyperlipoproteinemia Associated with Myxedema 181

5. Hyperlipoproteinemia Associated with Obesity and Excess Caloric Intake 181

References 182

CHAPTER 5

Lipoproteins and Lipoprotein Metabolism. S. EISENBERG and R. I. LEVY.
With 6 Figures

I. Structure and Functions of Lipoproteins. 191

A. Physical Properties 191

1. Chylomicrons 191

2. Very Low Density Lipoprotein 193

3. Low Density Lipoprotein 193

4. High Density Lipoprotein 193

B. Lipid Composition 193

C. The Apoprotein Moiety of Lipoproteins 194

D. Conclusion 197

II. Synthesis of Lipoproteins 197

A. Assembly, Intracellular Transport, and Release 197

B. Synthesis of Apoproteins 198

C. Regulation of Lipoprotein Synthesis 199

III. Lipoprotein Metabolism 200

A. Chylomicrons 200

B. Very Low Density Lipoproteins 202

C. Low Density Lipoprotein 204

D. High Density Lipoprotein 205

E. Conclusions 205

IV. The Hyperlipoproteinemias 206

Hyperlipoproteinemia Summary 207

V. Treatment of Hyperpoproteinemia 208

References 208

CHAPTER 6

Animal Models for Atherosclerosis Research. D. KRITCHEVSKY

I. Rabbit 216

II. Rat 219

III. Chicken 219

IV. Dog	219
V. Pigeons	220
VI. Swine	220
VII. Primates	221
References	223

CHAPTER 7

Lipoprotein Formation in the Liver Cell (Ultrastructural and Functional Aspects Relevant to Hypolipidemic Action). W. STÄUBLI and R. HESS. With 17 Figures

I. Introduction	229
II. The Concept of Membrane Flow and Its Relevance to Secretion	229
A. The Model	229
B. Individuality of Membrane Compartments	231
C. Directional Flow of Membranes	233
D. Energy Requirements of Secretion	234
III. Formation and Secretion of Lipoproteins	234
A. Evidence of the Secretion of Lipoproteins by the Hepatocyte	234
B. Synthesis of Lipoproteins on Ribosomes	234
C. Stepwise Glycosylation of Exportable Proteins by the Membrane-Bound Multiglycosyl Transferase System	235
D. Assembly of Protein and Lipid Moieties and Intracellular Transport	237
E. The Role of the Golgi Complex	240
F. Release from the Cell	246
G. Recapitulation	247
IV. Regulation of Lipoprotein Secretion	248
A. Compositional Variability of Lipoproteins	248
B. The Nature of Cytoplasmic Lipid Particles	248
C. Effects of Lipid-Lowering Agents	249
1. Actions of Aryloxyacetic Acids	249
2. Liver Induction in the Rodent	253
3. The Peroxisome Problem	254
4. Effects on Mitochondria	262
5. Relationship between VLDL-Containing Secretion Granules and Lysosomes	264
V. Concluding Remarks	265
References	266

CHAPTER 8

Vascular Metabolism, Vascular Enzymes, and the Effect of Drugs. T. ZEMPLÉNYI. With 13 Figures

I. Notes on Vascular Metabolism	291
Summary	297

II. Vascular Enzyme Studies	298
A. Enzymes in Venous Tissue	299
B. Interspecies and Intraspecies Differences	300
C. Effect of Age and Sex	301
D. Enzyme Activities in Vascular Grafts	302
E. Enzyme Activity in Atherosclerotic Vessels	302
F. The Role of Vascular Injury	309
G. Enzymes of Connective Tissue Metabolism	314
H. Enzymes Related to Lipid Metabolism	317
Summary	322
III. The Effect of Drugs	322
A. Bioflavonoids	323
B. Pyridinolcarbamate	325
C. Sex Hormones	326
D. Drugs Affecting Vascular Lipolytic and Esterolytic Activity	328
Summary	329
Concluding Remarks	330
Abbreviations	331
References	332

CHAPTER 9

Hypolipidemic Agents. W. L. BENCZE

I. Introduction	349
II. The Coronary Drug Project	350
III. Nicotinic Acid and Analogs	351
IV. Pyrazoles and Isoxazoles.	356
V. Diethyl Chelidonate.	357
VI. The Role of the Second Messenger in Lipolysis	357
VII. Catecholamines, Adrenergic Blocking Agents	358
VIII. Miscellaneous Inhibitors of Lipolysis	363
IX. The Prostaglandins	364
X. Thyroid Hormones	365
XI. Estrogens, Progestagens, Anabolic, and Androgenic Compounds	366
XII. Substituted Phenyl- and Phenyl-oxo-acetic Acids	371
XIII. Hepatic Action of Clofibrate and Its Analogs	376
A. Mitochondria	376
B. Microsomes	377
C. Peroxisomes (Microbodies).	378
D. Cytoplasm	379
XIV. Extrahepatic Enzymes Influenced by Clofibrate	380
XV. Potential Antiatherosclerotic Effect of Clofibrate	380
XVI. Derivatives of Dialkylaminoethanol	381
XVII. Unsaturated Fatty Acids	383

XVIII. Compounds Containing Sulfur	385
XIX. Indole-2-Carboxylic Acids	386
XX. Hydroxylamine Derivatives	386
XXI. Pyridinolcarbamate	387
XXII. Eritadenine	388
XXIII. Miscellaneous Compounds	389
XXIV. Cholestyramine	390
XXV. Neomycin	391
XXVI. Rifampin	392
XXVII. Concluding Remarks	392
References	395

CHAPTER 10

The Rationale for Hypolipemic Therapy. I. D. FRANTZ

Cholesterol Lowering by Diet	409
Conclusions from the Dietary Trials	409
Cholesterol Lowering with Clofibrate	411
Extrapolations between Different Lipid Lowering Techniques	411
Summary of Opinions	413
Conclusions	414
References	414

Author Index	417
-------------------------------	------------

Subject Index	483
--------------------------------	------------